United Kingdom In Vitro Diagnostics Market By Product (Instrument, Reagent, Other Products), By Test Type (Clinical Chemistry, Molecular Diagnostics, Hematology, Immuno Diagnostics, Other Types), By Usability (Disposable In Vitro Diagnostics Devices, Reusable In vitro Diagnostics Devices), By Application (Infectious Disease, Diabetes, Oncology, Cardiology, Autoimmune Disease, Nephrology, Others), By End User (Diagnostic Laboratories, Hospitals & Clinics, Others), By Region, Competition Forecast & Opportunities, 2018-2028F

The United Kingdom In Vitro Diagnostics Market is anticipated to grow significantly in the projected period, 2024-2028. The United Kingdom in vitro diagnostics market has experienced steady growth over the years, driven by factors such as an aging population, rising chronic diseases, and a focus on early detection and preventive care. The market encompasses a wide range of tests and technologies, including clinical chemistry, immunochemistry, molecular diagnostics, point-of-care testing, hematology, and microbiology, among others.

Testing carried out on human bodily tissue or blood samples is known as in vitro diagnostics (IVD). In vitro diagnostics can be used to monitor a person's overall health, diagnose diseases or other disorders, and help treat, prevent, or cure illnesses. Precision medicine may also make use of in vitro diagnostics to pinpoint patients who will likely benefit from particular medications or treatments, leading to the growth of the United Kingdom In Vitro Diagnostics Market. Next-generation sequencing tests, which scan a person's DNA to find genetic changes, can be a part of these in vitro diagnostics.

Rapid advancements in diagnostic technologies, such as next-generation sequencing, digital pathology, and lab automation, will revolutionize the in vitro diagnostics landscape. These innovations will enable faster and more accurate diagnoses, leading to improved patient outcomes and cost-effective healthcare, hence augmenting the growth of the United Kingdom In Vitro Diagnostics Market.

According to the Office for National Statistics, the cost of healthcare in the UK was estimated to be around USD350.83 billion in 2022, a rise in nominal terms of 0.7% over 2021. For chronic disorders to be treated quickly and effectively, early detection is essential. As a result, it is anticipated that demand for in-vitro diagnostic testing would rise. According to the International Agency for Research on Cancer, 51,983 new cases of lung cancer were reported in the United Kingdom in 2020, accounting for 11.8% of the total new cancer cases, which is 457,960.

In-vitro diagnostics is in high demand due to the need for early diagnosis and monitoring of various disorders utilizing imaging technologies for better disease management and treatment planning. This has resulted in a boom in the in-vitro diagnostics market in the United Kingdom.

The United Kingdom's population is aging quickly. According to the Office of National Statistics, almost 11 million persons, or 18.6% of the total population, were 65 years of age or older in 2021, compared to 16.4% at the time of the previous census in 2011. The need for in-vitro diagnostic tests is anticipated to increase since chronic diseases are more prevalent in the elderly. Additionally, the government of the United Kingdom is launching programs to raise awareness of the advantages of early detection, which is expected to drive the United Kingdom In Vitro Diagnostics Market in the forecast period.

Recent Advancements in Pharmacogenomics Drive United Kingdom's In Vitro Diagnostics Market

In the United Kingdom, recent advancements in pharmacogenomics have been instrumental in driving the growth of the in vitro diagnostics (IVD) market. Pharmacogenomics, the study of how an individual's genetic makeup influences their response to drugs, has revolutionized the field of healthcare. By combining genetics and genomics with traditional medicine, pharmacogenomics provides personalized treatment options that are tailored to a patient's genetic profile. This has led to the expansion of the United Kingdom In Vitro Diagnostics Market.

The National Health Service (NHS) in the United Kingdom has recognized the potential of pharmacogenomics and has started implementing guidelines for its incorporation into clinical practice. These guidelines help healthcare professionals make informed decisions based on a patient's genetic information, improving treatment outcomes and patient safety. Pharmacogenomics will be included in the ordinary National Health Service practice to provide patients with safer and more effective treatments, and to prevent wasting time and money on procedures that may be unsuccessful or even hazardous.

The development of high-throughput DNA sequencing and genotyping technologies has made it possible to rapidly and cost-effectively analyze an individual's genetic profile. These advancements have facilitated the integration of pharmacogenomics into routine clinical practice, thereby augmenting the growth of the United Kingdom In Vitro Diagnostics Market.

Rising Geriatric Population Revolutionize the United Kingdom In Vitro Diagnostics Market

The demand for IVD tests is anticipated to increase because chronic diseases are more prevalent in the elderly. Early diagnosis is essential for effective treatment in the geriatric population, which is why the United Kingdom In-vitro Diagnostics Market is growing. The geriatric population frequently suffers from multiple chronic diseases such as diabetes, cardiovascular conditions, and cancer. According to the House of Commons Library, the older population in the United Kingdom will increase, accounting for 24% of the total population (17.4 million people) by 2043. The percentage of people aged 75 and older is anticipated to increase from 8% in 2018 to 13% in 2043, while the percentage of people aged 85 and older is anticipated to increase from 2% to 4%.

Prevalence of Infectious Diseases

Infectious diseases pose a significant burden on public health systems and economies worldwide. The United Kingdom has faced outbreaks of diseases such as influenza, tuberculosis, hepatitis, sexually transmitted infections, and, recently, the COVID-19 pandemic. These outbreaks have highlighted the importance of rapid and accurate diagnostics for effective disease control and management. According to the Office of National Statistics 2019, allergy was the most frequently reported chronic health condition in both men and women (30.4% and 36.0%, respectively), followed by high blood pressure, low back disorder, and depression as the four most prevalent chronic conditions in the United Kingdom. In addition to having a negative impact on people's quality of life, chronic diseases place a heavy financial burden on the healthcare system. To facilitate early and accurate diagnosis of chronic diseases, monitor disease progression, and inform treatment choices, there has been an increasing demand for advanced in-vitro diagnostic technologies in the United Kingdom. This has caused the market for in-vitro diagnostics to grow in the United Kingdom, where a variety of modalities are being used. The growing understanding of the value of early disease detection and prevention is another factor influencing the growth of the in-vitro diagnostics market in the United Kingdom.

Download Free Sample Report

Recent Developments

• In January 2023, the majority of in-vitro diagnostic (IVD) devices will be evaluated by UL International UK Ltd, according to the Medicines and Healthcare products Regulatory Agency (MHRA). This will boost the United Kingdom's capacity to handle conformity assessments and ensure that safe and effective IVDs are available to UK citizens.
• In July 2022, Siemens Healthineers unveiled The Atellica CI 1900 Analyzer, a clinical chemistry and immunoassay testing system. It is a lower volume variant of their currently marketed Atellica clinical chemistry and immunoassay testing solution. The system has the ability to perform over 25,000 immunoassay tests annually and over 250,000 clinical chemistry tests annually. According to Siemens Healthineers, the new analyzer can be used as a stand-alone system in hub-and-spoke configurations connected to integrated delivery networks.

Mergers and Collaborations

• In March 2023, Agilent and Sophia Genetics collaborated to develop a cancer analysis solution. The partnership will integrate Agilent's SureSelect Cancer CGP Assay Kit and the SOPHiA DDM Platform, enabling clinical researchers to accurately identify a variety of biomarkers. This integration will reduce the possibility of omitting important information in cancer sample analysis.

Market Segmentation

The United Kingdom In Vitro Diagnostics Market is segmented by Product, Test Type, Usability, Application, End User, Region, and Competitive Landscape. Regarding Product, the market is divided into Instrument, Reagent, and Other Products. Test Types include Clinical Chemistry, Molecular Diagnostics, Hematology, Immuno Diagnostics, and Other Types. Usability category consist of Disposable In Vitro Diagnostics Devices and Reusable In vitro Diagnostics Devices. The Application segment includes Infectious Disease, Diabetes, Oncology, Cardiology, Autoimmune Disease, Nephrology, and others. End Users are categorized as Diagnostic Laboratories, Hospitals & Clinics, and Others. The market is further segmented by region, including Scotland, South-East, London, South-West, East-Anglia, Yorkshire & Humberside, and East Midlands.

Company Profiles

F. Hoffmann-La Roche Ltd., Abbott Laboratories, bioMérieux UK, Becton Dickinson and Company, Danaher Corporation, Agilent Technologies, Inc., Sysmex UK Ltd, Siemens Healthineers, Charles River Laboratories, Bio-Rad Laboratories, Inc are some of the key players of United Kingdom In Vitro Diagnostics market.

Report Scope:

In this report, United Kingdom In Vitro Diagnostics Market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

• United Kingdom In-vitro Diagnostics Market, By Product:
• Instrument
• Reagent
• Other Products
• United Kingdom In-vitro Diagnostics Market, By Test Type:
• Clinical Chemistry
• Molecular Diagnostics
• Hematology
• Immuno Diagnostics
• Other Types
• United Kingdom In-vitro Diagnostics Market, By Usability:
• Disposable In Vitro Diagnostics Devices
• Reusable In vitro Diagnostics Devices
• United Kingdom In-vitro Diagnostics Market, By Application:
• Infectious Disease
• Diabetes
• Oncology
• Cardiology
• Autoimmune Disease
• Nephrology
• Others
• United Kingdom In-vitro Diagnostics Market, By End User:
• Diagnostic Laboratories
• Hospitals & Clinics
• Others
• United Kingdom In Vitro Diagnostics Market, By Region:
• Scotland
• South-East
• London
• South-West
• East-Anglia
• Yorkshire & Humberside
• East Midlands

Competitive landscape

Company Profiles: Detailed analysis of the major companies in United Kingdom In Vitro Diagnostics market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

United Kingdom In Vitro Diagnostics Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]